Vào đêm trước kỷ nguyên hậu lượng tử: Bitcoin xây dựng thế hệ phòng thủ an ninh tiếp theo như thế nào?

Constellation Pharmaceuticals

company

About

Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.

  • 101 - 250

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$40M
Industries
Biotechnology,Genetics,Medical,Pharmaceutical
Founded date
Jan 1, 2008
Number Of Employee
101 - 250
Operating Status
Active

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$188.50M
Constellation Pharmaceuticals has raised a total of $188.50M in funding over 2 rounds. Their latest funding was raised on Mar 20, 2019 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 20, 2019 Post-IPO Debt $40M 1 Detail
Apr 9, 2018 Series F $100M 1 Detail
Jul 1, 2017 Series E $48.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Constellation Pharmaceuticals is funded by 2 investors. Hercules Capital and University of California Investment Office are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Post-IPO Debt
University of California Investment Office Series F